4503.T
$2443.50
Astellas Pharma Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric...
Recent News
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate
Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial reduction in tumor recurrence, progression, or death compared with standard chemotherapy. Data also pointed to a consistent safety profile for the combination regimen. The companies signaled that regulatory filings based on these results are expected. For you as an investor, this update sits at the...
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer
Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In. On February 27, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma announced positive Phase 3 EV-304 results for PADCEV, a Nectin-4-directed antibody-drug conjugate, in combination with Keytruda in patients with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy. Perioperative enfortumab vedotin plus […]
Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM
Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 clinical trial for PADCEVTM, a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda®, a PD-1 inhibitor, in patients with muscle-invasive bladder […]
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus
Vir Biotechnology (NasdaqGS:VIR) announced a global collaboration with Astellas Pharma to develop and commercialize VIR-5500 for metastatic castration-resistant prostate cancer. The agreement includes substantial upfront and near-term funding to support VIR-5500 and broader pipeline development. Positive Phase 1 data for VIR-5500 reported promising anti-tumor activity and safety in prostate cancer patients. The deal marks Vir's entry into high-profile immuno-oncology partnerships and...